LexaGene Holdings, Inc. is a molecular diagnostics company focused on the development and commercialization of automated genetic testing systems. The company’s flagship product, the MiQLab™, is a fully integrated platform that automates sample preparation, nucleic acid extraction, and real-time PCR analysis. Designed for a range of applications—from veterinary diagnostics and food safety testing to environmental monitoring and human health screening—the MiQLab™ streamlines the detection of multiple targets in a single run, offering rapid turnaround times and scalable throughput.
LexaGene’s technology is built around a proprietary cartridge-based workflow that minimizes manual handling and reduces the risk of cross-contamination. By coupling robotic liquid handling with multiplexed PCR chemistry, the system can identify a broad panel of pathogenic organisms and antimicrobial resistance markers in under an hour. The company continues to expand its menu of assays through in-house research and collaborations with reagent partners, aiming to address emerging threats and evolving regulatory requirements.
Headquartered in Woburn, Massachusetts, LexaGene serves diagnostic laboratories, veterinary clinics, food producers, and environmental testing facilities across North America and is exploring international channels for distribution. Under the leadership of President and CEO Jack Regan, the company has progressed through prototype validation, regulatory clearances, and initial commercial deployments. LexaGene’s strategic focus remains on driving adoption of point-of-need molecular diagnostics by offering a user-friendly, cost-effective solution for rapid pathogen detection.
AI Generated. May Contain Errors.
